Raresight
RareSight is a Swiss AI healthcare company that provides a clinical decision support platform helping clinicians, hospital systems, and pharmaceutical companies identify rare diseases earlier through pattern recognition across structured and unstructured patient data.
- Company typePrivate
- Founded-
- HeadquartersBettwil, Switzerland
- Headcount—
- GTM typeB2B
- OfferingSoftware
What Raresight does
RareSight AG (formerly RareSight GmbH) is a Swiss healthcare AI company headquartered in Bettwil, Switzerland, developing a clinical decision support platform aimed at earlier identification of rare diseases. Its proprietary system ingests both structured data (laboratory values, test results) and unstructured data (symptoms, clinical notes, medical history) to detect diagnostic patterns, surface potential rare disease matches, and present ranked differential diagnoses with guideline-matched evidence, citations, contradictions, and high-yield next-test recommendations. The platform is designed to operate within existing hospital workflows without manual data entry and is being built with an EU MDR medical device certification pathway, EU-hosted secure infrastructure, GDPR compliance, and WCAG 2.2 accessibility on its public surface.
The company sells through a B2B enterprise motion targeting three primary segments: clinicians and hospital systems for clinical decision support deployment, pharmaceutical companies developing rare disease therapies for patient identification and real-world data collaboration, and Clinical Research Organizations (CROs) for trial site pre-screening. The CRO/Trial Screening Layer is an add-on module designed to reduce clinical trial screen-fail rates from approximately 70% to approximately 50%. Pricing is not publicly disclosed; distribution is via direct enterprise field sales and collaborative pilots with clinicians and healthcare systems, with current operating geographies stated as Switzerland and Germany.
The three founders — Leon Thiel (CEO, ETH Zurich biochemistry background), Dr. Carsten Thiel (Chief Strategy & Commercial Officer, prior leadership of rare disease pharma companies), and Dr. Dev Kumar (Chief Legal & Medical Officer, trained medical doctor with pharma legal/strategy experience) — form the core management team. The company converted from a GmbH to an AG on April 23rd under the Swiss Merger Act (FusG) in preparation for future funding rounds, and was recognized with a 2026 Healthcare & Pharmaceutical Award from GHP News for "Most Innovative AI-Powered Rare Disease Diagnostics Platform - Switzerland."
Raresight firmographics
Firmographics- Name
- Raresight
- Legal name
- RareSight AG
- Website
- https://rare-sight.com
- Company type
- Private
- Operating status
- Operating
- Short description
- RareSight is a Swiss AI healthcare company that provides a clinical decision support platform helping clinicians, hospital systems, and pharmaceutical companies identify rare diseases earlier through pattern recognition across structured and unstructured patient data.
- Ownership category
- akta.pro rank
Raresight industry classification
Industry- Product category
- Clinical Decision Support Software
- NAICS
- Scientific Research and Development Services (5417), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Services-Health Services (8000)
- akta.pro primary industry
- Precision Clinical Trials Enablement (patient matching, site matching, adaptive trials) (HLAAANAI)
Keywords
Where Raresight is headquartered
LocationHeadquarters
- HQ city
- Bettwil
- HQ country
- Switzerland
- HQ region
- Europe
Offices2 records
Markets served
Raresight business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Technology or R&D, Personnel, Marketing or Sales, Operations
Revenue model
- Healthcare System Licensing: B2B licensing model targeting hospital systems and healthcare providers for clinical decision support deployment. Integration with existing hospital workflows. Enterprise-ready with EU-hosted secure infrastructure.
Go-to-market motion1 record
Distribution channels3 records
Marketing channels4 records
Raresight product offering
Product offeringCore offering
RareSight develops and sells an AI-powered clinical decision support platform that ingests structured and unstructured patient data (symptoms, labs, history, clinical notes) to detect diagnostic patterns suggestive of rare diseases. It surfaces ranked differential diagnoses with explainable, guideline-backed evidence and integrates directly into existing hospital workflows without requiring manual data entry. An associated CRO/trial screening layer pre-screens site records to identify eligible patients for rare disease clinical trials.
Product overview
Raresight offers a single unified AI-powered diagnostic decision support platform for rare disease identification. The core platform (RareSight AI Diagnostic Decision Support Platform) analyzes structured and unstructured patient data to detect rare disease patterns and provide explainable, guideline-backed diagnostic recommendations. An integrated CRO / Trial Screening Layer module extends the platform to support clinical trial site pre-screening, reducing screen-failure rates for rare disease studies.
Differentiator
Problem solved
Functional benefit
Products and services
- RareSight AI Diagnostic Decision Support Platform AI-powered clinical decision support software that analyzes structured and unstructured hospital patient data to detect rare disease signals, surface ranked differential diagnoses with guideline-matched citations, and explain its reasoning to clinicians within existing hospital workflows.
- CRO / Trial Screening Layer Clinical trial patient identification capability that pre-screens hospital site records to surface eligible candidates for rare disease clinical trials, designed to reduce screen-fail rates from approximately 70% to approximately 50%.
Quantifiable outcome
- Reduces average diagnostic odyssey from 6-8 years to potentially 4-6 years through earlier recognition
- +4 more outcomes
Companies that use Raresight
Customer profileSegments5 records
Ideal customer profiles3 records
Raresight technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability5 records
Feature5 records
Raresight partnerships and signals
Strategic signalPartnerships
Four partnerships are on record, tiered core and minor.
- Clinicians & Healthcare SystemscoreRareSight collaborates closely with clinicians, doctors, data scientists, and healthcare systems to ensure the tool is clinically relevant, technically robust, and easy to use. The product is designed with and for clinicians to shape a tool that truly fits clinical workflows.
- Pharmaceutical CompaniescorePartnership with rare disease therapy developers and industry leaders who understand the diagnostic bottleneck. Collaboration on real-world data, patient access, and unmet need to expand impact and align diagnostics with treatment.
- Researchers & Academic InstitutionsminorCollaboration with researchers in biomedical informatics, rare disease biology, or clinical research. Researchers contribute data, models, and expertise to strengthen algorithms and validate diagnostic pathways.
- Clinical Research Organizations (CROs)coreCRO partnerships for trial screening applications. RareSight pre-screens site records to surface eligible candidates, helping reduce screen-fail rates in clinical trials.
Scale indicators7 records
Recent moves7 records
Expansion highlights5 records
Raresight competitors and assessment
Company assessmentBroad incumbents
- Tempus AI: Large precision medicine AI platform offering clinical decision support, molecular diagnostics, and trial matching. Overlaps with RareSight's diagnostic decision support and CRO/trial screening capabilities, with a broader oncology-led portfolio.
- Foundation Medicine:
Direct peers
- SOPHiA Genetics: AI-driven clinical decision support for genomics and rare disease variant interpretation, deployed in hospital systems globally. Directly comparable to RareSight's AI pattern recognition and explainable diagnostic suggestions for rare disease identification.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks3 records
Key highlights6 records
Customer concentration
Raresight social profiles
Digital presenceRaresight compliance and trust
Trust signalCompliance3 records
Raresight financial estimates
Financial estimateRevenue estimate
Valuation estimate
Raresight leadership team
Management profileNumber of profiles
Profiles3 records
Raresight funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Raresight M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Raresight
What does Raresight do?
RareSight develops and sells an AI-powered clinical decision support platform that ingests structured and unstructured patient data (symptoms, labs, history, clinical notes) to detect diagnostic patterns suggestive of rare diseases. It surfaces ranked differential diagnoses with explainable, guideline-backed evidence and integrates directly into existing hospital workflows without requiring manual data entry. An associated CRO/trial screening layer pre-screens site records to identify eligible patients for rare disease clinical trials.
Is Raresight a public or private company?
Raresight is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was Raresight founded?
Raresight was founded in -1.
Where is Raresight based?
Raresight is headquartered in Bettwil, Switzerland, in the Europe region.
How does Raresight make money?
One revenue line is on record: healthcare System Licensing.
Who are Raresight's main competitors?
Broad incumbents on record are Tempus AI and Foundation Medicine. SOPHiA Genetics is listed as a direct peer.
Does Raresight have an API?
No public API is recorded for Raresight.
What industry is Raresight in?
Raresight's product category is Clinical Decision Support Software. Its primary akta.pro industry code is HLAAANAI, Precision Clinical Trials Enablement (patient matching, site matching, adaptive trials). Its NAICS code is 5417 and its SIC code is 8000.